Treatment for COVID-19 Positive Test
For outpatients with confirmed COVID-19 at high risk for severe disease, nirmatrelvir-ritonavir (Paxlovid) is the first-line treatment, with molnupiravir as an alternative when nirmatrelvir-ritonavir is contraindicated. 1, 2
Risk Stratification First
Immediately assess disease severity and risk factors:
High-risk patients include:
- Age ≥65 years
- Severe immunocompromise (hematological malignancies, recent B-cell depleting therapy, transplant recipients)
- Multiple comorbidities
- Unvaccinated or vaccine non-responders
Disease severity categories:
- Mild: No oxygen requirement, O2 saturation >94%
- Moderate: Requires supplemental oxygen, saturation 90-94%
- Severe: Saturation <90%, respiratory rate >30/min
- Critical: Mechanical ventilation, ARDS, septic shock
Treatment Algorithm by Severity
Mild COVID-19 (No Oxygen Requirement)
For high-risk patients:
- Nirmatrelvir-ritonavir 300/100 mg twice daily for 5 days - start within 5 days of symptom onset 1, 2, 3
- Reduces hospitalization (0.7% vs 1.2%) and mortality (<0.1% vs 0.2%) 2
- Critical caveat: Extensive drug interactions - review all medications before prescribing
If nirmatrelvir-ritonavir contraindicated:
- Molnupiravir 800 mg twice daily for 5 days 1, 2
- Increases recovery rate (31.8% vs 22.6%) and reduces time to recovery (9 vs 15 days) 2
- No mortality benefit but acceptable safety profile
For immunocompromised patients specifically:
- Consider monoclonal antibodies (sotrovimab) only after expert consultation as salvage therapy 4, 5
- High-titre convalescent plasma may be considered within 72 hours of symptom onset if antibodies unavailable 4
Do NOT use in mild disease:
- Dexamethasone or systemic corticosteroids 4, 6
- Remdesivir (insufficient evidence for outpatient use) 1
- Hydroxychloroquine, azithromycin, ivermectin 6, 2
Moderate COVID-19 (Requiring Oxygen, Saturation >90%)
Combination therapy:
- Remdesivir (if within 7 days of symptom onset) 4, 7
- Dexamethasone 6 mg daily for 10 days 4, 7, 6
- Anticoagulation with LMWH or NOAC (thromboprophylaxis mandatory) 8
If seronegative for SARS-CoV-2 antibodies:
- Add casirivimab/imdevimab or convalescent plasma 4
If worsening despite dexamethasone with COVID-19-related inflammation:
- Add second immunosuppressant: tocilizumab, sarilumab (anti-IL-6), or baricitinib (JAK inhibitor) 4, 7
Severe/Critical COVID-19 (Saturation <90% or Mechanical Ventilation)
Mandatory interventions:
- Remdesivir 4, 7
- Dexamethasone 6 mg daily (strong recommendation) 4, 7, 6
- Therapeutic anticoagulation 8
Add if COVID-19-related inflammation present and worsening:
For ventilated patients:
- High-titre convalescent plasma within 48 hours of intubation may be beneficial 7
- Consider combination of two antivirals or antiviral + monoclonal antibodies 7
Special Populations
Hematological Malignancy/Transplant Patients
Pre-exposure prophylaxis:
- Long-acting anti-SARS-CoV-2 monoclonal antibodies for unimmunized high-risk patients 4
Post-exposure prophylaxis:
- Anti-SARS-CoV-2 monoclonal antibodies for vaccine non-responders 4
Treatment modifications:
- Defer chemotherapy if moderate-severe COVID-19 9, 4
- May continue treatment in asymptomatic SARS-CoV-2 positive patients with close monitoring 4
- Defer cellular therapy (HSCT, CAR-T) until COVID-19 resolution 4
- Continue JAK2-inhibitors and TKI/BTKi 4
Critical Timing Considerations
All antiviral therapies are most effective when started within 5 days of symptom onset 1, 3. Do not delay treatment while awaiting specialist consultation in high-risk patients.
What NOT to Do
Strong recommendations against:
- Hydroxychloroquine (any setting) 6
- Lopinavir-ritonavir 6
- Azithromycin alone 6
- Colchicine 6
- Ivermectin 2
- Remdesivir in patients requiring invasive mechanical ventilation 6
- G-CSF outside standard indications (risk of worse COVID-19 outcomes) 4